Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes
Idiopathic orbital inflammation (IOI) is a noninfectious inflammatory disease whose etiology remains unknown. Treatment is focused on reducing inflammation, which becomes challenging in nonresponding cases. We report the case of a 59-year-old woman with refractory IOI that showed a positive response...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-07-01
|
| Series: | Case Reports in Ophthalmology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/508237 |
| _version_ | 1818581978823262208 |
|---|---|
| author | June Artaechevarria Artieda Ignacio Tapias Elias |
| author_facet | June Artaechevarria Artieda Ignacio Tapias Elias |
| author_sort | June Artaechevarria Artieda |
| collection | DOAJ |
| description | Idiopathic orbital inflammation (IOI) is a noninfectious inflammatory disease whose etiology remains unknown. Treatment is focused on reducing inflammation, which becomes challenging in nonresponding cases. We report the case of a 59-year-old woman with refractory IOI that showed a positive response to tocilizumab therapy. The patient was diagnosed with a unilateral sclerosing IOI for 9 years and showed a negative control with previous oral steroids, peribulbar steroid injections, radiotherapy, immunosuppressors, and intravenous rituximab. After the initiation of 8 mg/kg intravenous tocilizumab, a complete reduction of the pain and the orbital inflammation signs was observed and her condition remained stable for the following 6 years under a monthly dose of 4 mg/kg. In recalcitrant IOI cases, tocilizumab could be considered a possible treatment to reduce inflammatory signs and symptoms with positive long-term outcomes as in our case. |
| first_indexed | 2024-12-16T07:42:05Z |
| format | Article |
| id | doaj.art-bfb9504cd9b9459f8cd0c05e83949048 |
| institution | Directory Open Access Journal |
| issn | 1663-2699 |
| language | English |
| last_indexed | 2024-12-16T07:42:05Z |
| publishDate | 2020-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Ophthalmology |
| spelling | doaj.art-bfb9504cd9b9459f8cd0c05e839490482022-12-21T22:39:03ZengKarger PublishersCase Reports in Ophthalmology1663-26992020-07-0111229930510.1159/000508237508237Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up OutcomesJune Artaechevarria ArtiedaIgnacio Tapias EliasIdiopathic orbital inflammation (IOI) is a noninfectious inflammatory disease whose etiology remains unknown. Treatment is focused on reducing inflammation, which becomes challenging in nonresponding cases. We report the case of a 59-year-old woman with refractory IOI that showed a positive response to tocilizumab therapy. The patient was diagnosed with a unilateral sclerosing IOI for 9 years and showed a negative control with previous oral steroids, peribulbar steroid injections, radiotherapy, immunosuppressors, and intravenous rituximab. After the initiation of 8 mg/kg intravenous tocilizumab, a complete reduction of the pain and the orbital inflammation signs was observed and her condition remained stable for the following 6 years under a monthly dose of 4 mg/kg. In recalcitrant IOI cases, tocilizumab could be considered a possible treatment to reduce inflammatory signs and symptoms with positive long-term outcomes as in our case.https://www.karger.com/Article/FullText/508237idiopathic orbital inflammationtocilizumaborbitinflammationeye |
| spellingShingle | June Artaechevarria Artieda Ignacio Tapias Elias Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes Case Reports in Ophthalmology idiopathic orbital inflammation tocilizumab orbit inflammation eye |
| title | Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
| title_full | Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
| title_fullStr | Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
| title_full_unstemmed | Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
| title_short | Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes |
| title_sort | tocilizumab in a case of refractory idiopathic orbital inflammation 6 year follow up outcomes |
| topic | idiopathic orbital inflammation tocilizumab orbit inflammation eye |
| url | https://www.karger.com/Article/FullText/508237 |
| work_keys_str_mv | AT juneartaechevarriaartieda tocilizumabinacaseofrefractoryidiopathicorbitalinflammation6yearfollowupoutcomes AT ignaciotapiaselias tocilizumabinacaseofrefractoryidiopathicorbitalinflammation6yearfollowupoutcomes |